Macular Edema - Pipeline Review, H2 2017

Date: November 30, 2017
Pages: 42
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: MD75D55BE2DEN
Leaflet:

Download PDF Leaflet

Macular Edema - Pipeline Review, H2 2017
Macular Edema - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H2 2017, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.

Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Macular Edema - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 7 and 2 respectively.

Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Macular Edema - Overview
Macular Edema - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Macular Edema - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Macular Edema - Companies Involved in Therapeutics Development
ActiveSite Pharmaceuticals Inc
Coherus BioSciences Inc
Lupin Ltd
Mabion SA
OMEICOS Therapeutics GmbH
Promedior Inc
Taiwan Liposome Company Ltd
Xbrane Biopharma AB
Macular Edema - Drug Profiles
ACX-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASPPDC-020 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dexamethasone sodium phosphate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HO-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMT-28 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRM-167 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranibizumab biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Macular Edema - Dormant Projects
Macular Edema - Discontinued Products
Macular Edema - Product Development Milestones
Featured News & Press Releases
Jul 25, 2017: TLC to Receive Government Grant for Development of Ophthalmology Product Candidate TLC399
Oct 01, 2015: Patent Granted by SIPO for TLCs Ophthalmic Drug Delivery System
Jan 06, 2015: Government Subsidy of NT$17.6M granted for TLC’s Ophthalmology Drug Phase I/II trial
Dec 23, 2013: TLC receives FDA IND approval for Sustained Release Macular Disease Drug
Sep 24, 2013: Patent Approval granted by USPTO for TLC’s BioSeizer Platform
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Macular Edema, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Macular Edema - Pipeline by ActiveSite Pharmaceuticals Inc, H2 2017
Macular Edema - Pipeline by Coherus BioSciences Inc, H2 2017
Macular Edema - Pipeline by Lupin Ltd, H2 2017
Macular Edema - Pipeline by Mabion SA, H2 2017
Macular Edema - Pipeline by OMEICOS Therapeutics GmbH, H2 2017
Macular Edema - Pipeline by Promedior Inc, H2 2017
Macular Edema - Pipeline by Taiwan Liposome Company Ltd, H2 2017
Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2017
Macular Edema - Dormant Projects, H2 2017
Macular Edema - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Macular Edema, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

ActiveSite Pharmaceuticals Inc
Coherus BioSciences Inc
Lupin Ltd
Mabion SA
OMEICOS Therapeutics GmbH
Promedior Inc
Taiwan Liposome Company Ltd
Xbrane Biopharma AB
Skip to top


Diabetic Macular Edema - Pipeline Review, H2 2017 US$ 2,000.00 Jul, 2017 · 193 pages

Ask Your Question

Macular Edema - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: